Pigmented Villonodular Synovitis Clinical Trial
Official title:
Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)
The purpose of this study is to explore the efficacy of nilotinib as a treatment of patients
with progressive or relapsing pigmented villo-nodular synovitis / tenosynovial giant cell
tumour (PVNS/TGCT) who cannot be treated by surgery.
The primary objective of the study will be to determine the efficacy of 12 weeks (3 months)
of nilotinib treatment as measured by the non progression rate (Complete response + Partial
Response + Stable disease according to Response Evaluation Criteria In Solid Tumours -
RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be
treated by surgery.
this study is an international, multicentre, non-randomized, open-label phase II clinical
trial with a Bayesian design.
A maximum sample size of 50 patients will be included in the study
A key secondary objective of the study will be to determine the efficacy of 24 weeks (6
months) of nilotinib treatment as measured by the non progression rate (Complete response +
Partial Response + Stable disease according to Response Evaluation Criteria In Solid Tumours
- RECIST version 1.1) in patients with progressive or relapsing PVNS/TGCT who cannot be
treated by surgery.
This key secondary objective was defined for the purpose of a further analysis (not
described in this protocol) which will pool the data of the PVNS study with those of a
similar concomitant study conducted in the US and Australia.
The other secondary objectives will be:
To evaluate the efficacy of nilotinib according to:
- The objective tumour response rate (Complete response + Partial Response according to
RECIST version 1.1) after 12 weeks of treatment
- The duration of treatment response
- The best overall response obtained during the study
- The progression-free survival (PFS)
- The time to progression (TTP)
- The time to treatment failure (TTF)
- The proportion of patients with an operable tumour after nilotinib exposure according
to investigator evaluation
- The description of concomitant treatments use
- The correlation between trough levels of nilotinib and objective tumour response To
assess the safety of nilotinib for PVNS/TGCT patients
An exploratory objective of the study will be to study the relationship between the
objective tumour response and the following tumour characteristics (tissues collected in a
prior surgery, or by biopsy, upon specific acceptance by the patient; if no tissue is
available in the prior surgery, a biopsy will be done at visit 2):
Presence of COL6A3/CSF1 fusion gene Presence of M-CSF, CSF1R, KIT, PDGFRA and B on
immunohistochemistry Presence of phosphorylated c-fms on tumour samples Activation of the
PI3K/Akt/mTor pathway, presence of activating mutations of ras, and other potential
molecular alterations
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01207492 -
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
|
Phase 2 | |
Terminated |
NCT04938180 -
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
|
Phase 2 | |
Active, not recruiting |
NCT05059262 -
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
|
Phase 3 | |
Active, not recruiting |
NCT04731675 -
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
|
Phase 2 | |
Completed |
NCT02371369 -
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
|
Phase 3 | |
Completed |
NCT02471716 -
Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
|
Phase 1/Phase 2 | |
Recruiting |
NCT05349643 -
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
|
Phase 2 | |
Completed |
NCT04952896 -
Clinical Study of Magnetic Resonance Imaging and Deep Learning of Joint Synovial Disease
|
||
Active, not recruiting |
NCT03069469 -
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
|
Phase 1/Phase 2 | |
Completed |
NCT04955535 -
Screening of Specific Genes for Pigmented Villous Nodular Synovitis
|
||
Active, not recruiting |
NCT05804045 -
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
|
Phase 3 | |
Completed |
NCT01643850 -
MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
|
Phase 2 |